| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1918652 | Maturitas | 2007 | 12 Pages |
Abstract
According to the results, Tibolone seems to be a cost-effective alternative to CEE/MPA. However, those results should be interpreted with caution insofar as the difference in terms of QALY is clinically difficult to value and taking into account the limited data on Tibolone's long-term innocuity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Vakaramoko Diaby, Sylvie Perreault, Jean Lachaine,